A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
ACTIVE_NOT_RECRUITING
Status
Conditions
- Metastatic Esophageal Carcinoma
- Advanced Unresectable Gastric Adenocarcinoma
- Metastatic Gastric Cancer
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Metastatic Esophageal Cancer
- Metastatic Esophageal Adenocarcinoma
- Metastatic Gastric Adenocarcinoma
- Metastatic Gastric Carcinoma
- Unresectable Esophageal Cancer
- Unresectable Esophageal Adenocarcinoma
- Unresectable Gastric Carcinoma
- Unresectable Gastric Adenocarcinoma
- Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
- BIOLOGICAL: AgenT-797
- BIOLOGICAL: Botensilimab
- DRUG: Balstilimab
- DRUG: Ramucirumab
- DRUG: Paclitaxel
Sponsor
Memorial Sloan Kettering Cancer Center